For years, the agency maintained three distinct categories for substances used in compounding: Category 1: Substances that have been evaluated and determined to be eligible for compounding because they do not present significant safety risks and meet clinical needs
Research has examined NNMT inhibition and its downstream effects on cellular NAD+ salvage, methylation balance and adipocyte energy metabolism, with preclinical work exploring roles in lipid handling and metabolic regulation
This makes it suitable for capsule-based research protocols
While we observed significant changes in gene expression and cellular function, the direct causal relationship with improved IVF outcomes requires further investigation
Both of these agents deserve respect, and the safety data is there to support their use under proper medical guidance
BMJ Case Reports, 2018, bcr-2017